NEVVI Medicare utilization intelligence
or

← back

Provider profile

FORAN, JAMES MD

Hematology-Oncology · NPI 1992749139 · JACKSONVILLE, FL

1
Groups
51
Codes · 2024
51,878
Disclosed services

FORAN, JAMES is a Hematology-Oncology in JACKSONVILLE, FL, a member of 1 medical group, who billed 51 distinct codes to Medicare Part B in 2024.

Groups: MAYO CLINIC JACKSONVILLE (JACKSONVILLE, FL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider analytics (2024)

FORAN, JAMES billed 58,722 disclosed services in CY2023 and 51,878 in CY2024.

This provider's disclosed Medicare payments across all codes were $ in CY2024.

The full figure is part of the market analytics platform — built, not launched yet. Notify me at launch →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1453 Injection, fosaprepitant, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9264 Injection, paclitaxel protein-bound particles, 1 mg
J9267 Injection, paclitaxel, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J2469 Injection, palonosetron hcl, 25 mcg
J9041 Injection, bortezomib, 0.1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
96375 Injection of additional new drug or substance into vein
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
96413 Administration of chemotherapy into vein, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J9045 Injection, carboplatin, 50 mg
36591 Collection of blood sample from implanted device
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J9190 Injection, fluorouracil, 500 mg
96372 Injection of drug or substance under skin or into muscle
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
96361 Infusion into a vein for hydration, each additional hour
J9060 Injection, cisplatin, powder or solution, 10 mg
J7030 Infusion, normal saline solution , 1000 cc
96417 Administration of additional new drug or substance into vein, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96360 Infusion into a vein for hydration, 31-60 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96374 Injection of drug or substance into vein
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96411 Administration of additional new drug or substance into vein using push technique
99238 Hospital discharge day management, 30 minutes or less
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.